News stories about Fresenius Medical Care (NYSE:FMS) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fresenius Medical Care earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.5427883038605 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Quest Diagnostics Buys Fresenius Medical's Shiel Laboratory (finance.yahoo.com)
- Fresenius Medical Care : closes divestment of Shiel Medical Laboratory to Quest Diagnostics (4-traders.com)
- FMC – Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care closes divestment of Shiel Medical Laboratory to Quest Diagnostics (twst.com)
- Morgan Stanley Lowers Fresenius Medical Care (FMS) to Equal (americanbankingnews.com)
- ETFs with exposure to Fresenius Medical Care AG & Co. KGaA : December 7, 2017 (finance.yahoo.com)
A number of research analysts have issued reports on FMS shares. Royal Bank of Canada reissued a “hold” rating and set a $44.00 price objective on shares of Fresenius Medical Care in a report on Wednesday, September 13th. Zacks Investment Research cut Fresenius Medical Care from a “buy” rating to a “sell” rating in a report on Wednesday, October 25th. Morgan Stanley cut Fresenius Medical Care from an “overweight” rating to an “equal weight” rating in a report on Monday. Finally, DZ Bank reaffirmed a “buy” rating on shares of Fresenius Medical Care in a report on Monday, November 13th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. Fresenius Medical Care currently has a consensus rating of “Hold” and an average price target of $48.50.
Fresenius Medical Care (NYSE FMS) traded up $0.35 during trading on Wednesday, hitting $51.94. The company had a trading volume of 103,100 shares, compared to its average volume of 180,557. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.22 and a quick ratio of 0.98. Fresenius Medical Care has a fifty-two week low of $39.46 and a fifty-two week high of $51.98. The company has a market capitalization of $31,765.10, a PE ratio of 23.14, a price-to-earnings-growth ratio of 2.32 and a beta of 0.45.
ILLEGAL ACTIVITY WARNING: This news story was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://ledgergazette.com/2017/12/13/fresenius-medical-care-fms-receiving-somewhat-positive-news-coverage-analysis-finds.html.
Fresenius Medical Care Company Profile
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.